%PDF-1.4
%
25 0 obj
<>
endobj
22 0 obj
<>
endobj
83 0 obj
<>stream
Acrobat Distiller 4.05 for Macintosh
2003-03-05T14:17:13Z
2024-03-28T12:22:30-07:00
QuarkXPressª 4.11: AdobePS 8.6 (219)
2024-03-28T12:22:30-07:00
application/pdf
Heather
2002-774.april
uuid:9ee1e26c-1dd1-11b2-0a00-ef09277d8900
uuid:9ee1e26f-1dd1-11b2-0a00-d30000000000
endstream
endobj
11 0 obj
<>
endobj
12 0 obj
<>
endobj
26 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
1 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
4 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
7 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
97 0 obj
[101 0 R]
endobj
98 0 obj
<>stream
1 g
/GS0 gs
0 792 m
0 792 l
f
q
-1 793 614 -794 re
W n
q
0 792.03 612 -792 re
W n
BT
/CS0 cs 0 0 0 1 scn
/GS1 gs
/T1_0 1 Tf
-0.00011 Tc 0.0739 Tw 10 0 0 10 54 713.1616 Tm
(is the sustained down-regulation in the production of IL-6,)Tj
0.00819 Tw 0 -1.2 TD
(which represents the main inducer molecule of the systemic)Tj
0.02499 Tw T*
(acute phase reaction in PMR. )Tj
/T1_1 1 Tf
0 Tw 0 -2.4 TD
(REFERENCES)Tj
/T1_0 1 Tf
0.02499 Tw 8 0 0 8 61 655.1616 Tm
[(1.)-875.1 (Salvarani C, Macchioni PL, Boiardi L. Polymyalgia rheumatica.)]TJ
1.675 -1.25 Td
(Lancet 1997;350:43-7.)Tj
-1.675 -1.25 Td
[(2.)-875.1 (Kyle )17.7 (V)128.9 (, Hazleman BL. Stopping steroids in polymyalgia rheumatica)]TJ
1.675 -1.25 Td
(and giant cell arteritis. BMJ 1990;300:344-5.)Tj
-1.675 -1.25 Td
[(3.)-875.1 (Andersson R, Malmvall B-E, Bengtsson B-A. Long-term )]TJ
1.675 -1.25 Td
[(corticosteroid treatment in giant cell arteritis. )54.8 (Acta Med Scand)]TJ
0 Tc 0 Tw 0 -1.25 TD
(1986;220:465-9.)Tj
-0.00011 Tc 0.02499 Tw -1.675 -1.25 Td
[(4.)-875.1 (Salvarani C, Cantini F)79.7 (, Macchioni PL, et al. Distal musculoskeletal)]TJ
1.675 -1.25 Td
(manifestations in polymyalgia rheumatica: a prospective follow-up)Tj
T*
[(study)64.9 (. )54.8 (Arthritis Rheum 1998;41:1221-6.)]TJ
-1.675 -1.25 Td
[(5.)-875.1 (Salvarani C, Macchioni PL, )17.7 (T)69.9 (artoni PL, et al. Polymyalgia)]TJ
1.675 -1.25 Td
(rheumatica and giant cell arteritis: a 5-year epidemiologic and )Tj
T*
[(clinical study in Reggio Emilia, Italy)64.8 (. Clin Exp Rheumatol)]TJ
0 Tc 0 Tw T*
(1987;5:205-15.)Tj
-0.00011 Tc 0.02499 Tw -1.675 -1.25 Td
[(6.)-875.1 (Gabriel SE, Sunku J, Salvarani C, et al. )54.8 (Adverse outcomes of )]TJ
1.675 -1.25 Td
(antiinflammatory therapy among patients with polymyalgia)Tj
T*
[(rheumatica. )54.8 (Arthritis Rheum 1997;40:1873-8.)]TJ
-1.675 -1.25 Td
[(7.)-875.1 (Ferraccioli GF)79.7 (, Di Poi E, Damato R. Steroid sparing therapeutic)]TJ
1.675 -1.25 Td
(approaches to polymyalgia rheumatica-giant cell arteritis. State of)Tj
T*
(art and perspectives. Clin Exp Rheumatol 2000;18 Suppl 20:58-60.)Tj
-1.675 -1.25 Td
[(8.)-875.1 (Lipsky PE, van der Heijde DMFM, St. Clair EW)91.7 (, et al. Infliximab)]TJ
1.675 -1.25 Td
(and methotrexate in the treatment of rheumatoid arthritis. N Engl J)Tj
0 Tc T*
(Med 2000;343:1594-602. )Tj
-0.00011 Tc -1.675 -1.25 Td
[(9.)-875.1 (Brandt J, Haibel H, Cornely D, et al. Successful treatment of active)]TJ
1.675 -1.25 Td
(ankylosing spondylitis with anti-tumor necrosis factor alpha)Tj
T*
[(monoclonal antibody infliximab. )54.8 (Arthritis Rheum 2000;43:1346-52.)]TJ
30.825 38.671 Td
[(10.)-875.1 (Cantini F)79.7 (, Niccoli L, Salvarani C, Padula )54.8 (A, Olivieri I. )17.7 (T)35 (reatment of)]TJ
2.175 -1.25 Td
(longstanding active giant cell arteritis with infliximab: report of 4)Tj
T*
[(cases. )54.8 (Arthritis Rheum 2001;44:2933-5.)]TJ
-2.1381 -1.25 Td
[(1)36.8 (1)-0.1 (.)-875.1 (Healey LA. Long-term follow-up of polymyalgia rheumatica:)]TJ
2.1381 -1.25 Td
[(evidence for synovitis. Semin )54.8 (Arthritis Rheum 1984;13:322-8.)]TJ
-2.175 -1.25 Td
[(12.)-875.1 (V)110.8 (an der )17.7 (V)110.8 (een MJ, Dinant HJ, van Booma-Frankfort C, et al. Can)]TJ
2.175 -1.25 Td
(methotrexate be used as a steroid sparing agent in the treatment of)Tj
T*
[(polymyalgia rheumatica and giant cell arteritis? )54.8 (Ann Rheum Dis)]TJ
0 Tc 0 Tw T*
(1996;55:218-23.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(13.)-875.1 (Roche NE, Fulbright JW)91.7 (, )17.7 (W)79.9 (agner )54.8 (AD, et al. Correlation of )]TJ
2.175 -1.25 Td
(interleukin-6 production and disease activity in polymyalgia)Tj
T*
[(rheumatica and giant cell arteritis. )54.8 (Arthritis Rheum 1993;)]TJ
0 Tc 0 Tw T*
(36:1286-94.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(14.)-875.1 (Uddhammar )54.8 (A, Sundquist K-G, Ellis E, Rantapaa-Dahlqvist S.)]TJ
2.175 -1.25 Td
(Cytokines and adhesion molecules in patients with polymyalgia)Tj
T*
(rheumatica. Br J Rheumatol 1998;37:766-9.)Tj
-2.175 -1.25 Td
[(15.)-875.1 (Mattey DL, Hajeer )54.8 (AH, Dababneh )54.8 (A, et al. )54.8 (Association of giant cell)]TJ
2.175 -1.25 Td
[(arteritis and polymyalgia rheumatica with dif)17.7 (ferent tumor necrosis)]TJ
T*
[(factor microsatellite polymorphisms. )54.8 (Arthritis Rheum)]TJ
0 Tc 0 Tw T*
(2000;43:1749-55.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(16.)-875.1 (W)79.9 (eyand CM, Fulbright JW)91.7 (, Evans JM, Hunder GG, Goronzy JJ.)]TJ
2.175 -1.25 Td
[(Corticosteroid requirements in polymyalgia rheumatica. )54.8 (Arch Intern)]TJ
0 Tc T*
(Med 1999;159:577-84.)Tj
-0.00011 Tc -2.175 -1.25 Td
[(17.)-875.1 (W)79.9 (eyand CM, Fulbright JW)91.7 (, Hunder GG, Evans JM, Goronzy JJ.)]TJ
2.175 -1.25 Td
[(T)35 (reatment of giant cell arteritis. Interleukin-6 as a biologic marker)]TJ
T*
[(of disease activity)64.8 (. )54.8 (Arthritis Rheum 2000;43:1041-8.)]TJ
-2.175 -1.25 Td
[(18.)-875.1 (Butler DM, Maini RN, Feldmann M, Brennan FM. Modulation of)]TJ
2.175 -1.25 Td
(proinflammatory cytokine release in rheumatoid synovial)Tj
T*
[(membrane cell cultures. Comparison of monoclonal anti )17.7 (TNF-alpha)]TJ
T*
(antibody with the interleukin-1 receptor antagonist. Eur Cytokine)Tj
T*
(Netw 1995;6:225-30. )Tj
ET
0 0 0 0 scn
424 777 133 -27 re
f*
428 770 130 -25 re
f*
/CS0 CS 0 0 0 1 SCN
54 54 m
558 54 l
S
BT
0 0 0 1 scn
/T1_2 1 Tf
8 0 0 8 54.5 35.9844 Tm
(Salvarani, et al: Infliximab in PMR)Tj
0 Tc 0 Tw 61.4375 -0.0313 Td
(763)Tj
ET
0 0 0 0 scn
/GS0 gs
109.22 59.09 396.48 -10.84 re
f*
0.5 w
109.22 59.09 396.48 -10.84 re
S
Q
Q
q
0 0 612 792 re
W n
BT
0 0 0 rg
/GS2 gs
/T1_3 8 Tf
117.48 51 Td
(Personal, non-commercial use only. The Journal of Rheumatology Copyrig\
ht \251 2003. All rights reserved.)Tj
ET
Q
BT
0 g
/GS2 gs
/T1_4 1 Tf
10 0 0 10 540 17 Tm
( )Tj
0 0.48627 0.77255 rg
/GS2 gs
-7.22298 0 Td
(www.jrheum.org)Tj
0 g
/GS2 gs
-16.72996 0 Td
(Downloaded on March 28, 2024 from )Tj
ET
endstream
endobj
39 0 obj
<>
endobj
50 0 obj
<>
endobj
31 0 obj
<>
endobj
74 0 obj
<>
endobj
88 0 obj
<>
endobj
28 0 obj
<>
endobj
66 0 obj
<>stream
HUkTSW7Q$jQ
hE2#JxHHy ȳBtU5U|TQ)3vfDY1k>[g}q%`ΐ-"i"يy\8U~8A{[vѱ21ʱW>JIhUV9,;a$k:Wyy{nd(Ir҄_ W_uDIHK!d4C"T^P*ٶ2aP.KISPqD q+%R'ˊqRHs!me`,̝~Vav,0La0lmX}Y80sxn@!˘.L,v*(oq|Ë9ΙX
{ѼK:s6:sIpyIQ']YU:sx\[(KD
8:dIkVW'iE1y,'-OV%* sD
g{3ĽaJbX,IVă[nuo[çw o]@EƬmDhQÁcψ.}zCfopxF͡^5ꋾP636Kjk2.